Table 2.

Trials investigating targeted therapy in advanced HCC

Trial name/identifier	Patient no.	Study type	Line	Interventions	Primary endpoint	Study status
IMbrave150/ NCT03434379	480	Phase III	First	Atezolizumab + bevacizumab vs Sorafenib	OS, PFS	Completed
ZGDH3/NCT02645981	668	Phase II/III	First	Donafenib vs sorafenib	OS	Completed
HIMALYYA/ NCT03298451	1310	Phase III	First	Durvalumab + tremelimumab vs sorafenib	OS	Ongoing
RATIONALE-301 / NCT03412773	674	Phase III	First	Tislelizumab vs sorafenib	OS	Ongoing
PHOCUS	600	Phase III	First	Pexa-Vec + sorafenib vs sorafenib	OS	Ongoing
NCT04344158	648	Phase III	First	AK105 + anlotinib vs sorafenib	OS	Ongoing
ALTER0802/ NCT02809534	60	Phase II	First	Anlotinib	PFS 12W	Ongoing
AHELP/NCT02329860	400	Phase III	Second	Apatinib vs placebo	OS	Completed
KEYNOTE-394 / NCT03062358	450	Phase III	Second	Pembrolizumab + BSC vs placebo + BSC	OS	Ongoing
NCT04080154	28	Phase II	Second	Anlotinib	PFS	Ongoing

OS overall survival, PFS progression-free survival, BSC best supportive care